• Kymera Therapeutics COO Jeremy G. Chadwick sold 17,184 shares on May 26-27, cutting his stake to 44,018 shares.
• Sales were priced between USD 78.36 and USD 82.08 per share, based on reported weighted-average execution prices.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-242266), on May 27, 2026, and is solely responsible for the information contained therein.